The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Increase In Market Value Is Predicted For The Cancer Immunotherapy Market During The 2026–2030 Period?
The cancer immunotherapy market has experienced rapid expansion in recent years. It is projected to increase from $124.09 billion in 2025 to $137.99 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.2%. This historical growth can be attributed to significant advancements in tumor immunology, a global rise in cancer incidence, the early efficacy of monoclonal antibodies, increased funding for oncology research and development, and regulatory clearances for checkpoint inhibitors.
The cancer immunotherapy market size is projected for substantial growth over the upcoming years. It is anticipated to reach $210.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.1%. This expansion during the forecast period is fueled by factors such as the increasing acceptance of CAR T-cell therapies, the broadening of applications into solid tumor indications, heightened investment in cancer vaccines, a growing need for targeted combination therapies, and supportive reimbursement frameworks for immunotherapy. Key developments expected during this period involve the accelerated uptake of immune checkpoint inhibitors, a rise in the application of combination immunotherapy regimens, the extension of cell-based cancer therapies, an increased emphasis on personalized immunotherapy, and a surge in oncology clinical trials.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp
What Core Drivers Are Transforming The Cancer Immunotherapy Market?
The increasing occurrence of cancer is expected to drive growth in the cancer immunotherapy market. Global cancer cases are on the rise due to factors such as tobacco use, alcohol consumption, obesity, inactive lifestyles, and environmental influences. This growth in cancer incidence is anticipated to boost the need for cancer immunotherapies, as patients are increasingly seeking medical treatments that offer improved recovery and reduced discomfort. For example, in July 2024, according to forecasts released by Cancer Research UK, a UK-based cancer charity, cancer incidence rates in the United Kingdom are projected to increase for most types between 2023-2025 and 2038-2040, with rises varying from less than 1% for breast cancer to 50% for eye cancer. Conversely, a smaller number of cancers are expected to decline, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Consequently, the expanding incidence of cancer is predicted to fuel demand for cancer immunotherapy throughout the forecast period.
How Is The Cancer Immunotherapy Market Examined Through Segment Analysis?
The cancer immunotherapy market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy
2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma
3) By End User: Hospitals, Cancer Research Centers, Clinics
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists
4) By Vaccines: Therapeutic Cancer Vaccines
5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy
Which Trends Are Supporting The Evolution Of The Cancer Immunotherapy Market?
Leading companies in the cancer immunotherapy market are concentrating on developing innovative solutions, such as PD-1 immunotherapies, to broaden the availability of advanced immune-based treatment options for patients with challenging cancers. A PD-1 immunotherapy is an immune checkpoint-targeting treatment designed to stimulate antitumor immune activity by blocking programmed death-1 pathway interactions. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical company specializing in oncology and biologics, introduced HETRONIFLY (Serplulimab). This therapy is the first programmed death-1 inhibitor globally approved for extensive-stage small cell lung cancer and employs a dual mechanism targeting PD-L1 and PD-L2 with strong receptor internalization to enhance immune engagement. Its demonstrated survival benefit and significantly reduced cost compared with existing immunotherapies emphasize its clinical value and expand patient access to advanced cancer treatment in India.
Which Organizations Are Operating Within The Cancer Immunotherapy Market?
Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.
Access The Complete Cancer Immunotherapy Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Which Region Has The Strongest Presence In The Cancer Immunotherapy Market?
North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Cancer Immunotherapy Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp
Browse Through More Reports Similar to the Global Cancer Immunotherapy Market 2026, By The Business Research Company
Cancer Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Cellulars Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
Allergy Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model